Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In the assessment of 12-month price targets, analysts unveil insights for 10x Genomics, presenting an average target of ...

Genomics announced new multi year collaborations in cancer research with PharosAI, the Cancer Research Institute, and Dana Farber Cancer Institute. The partners plan to use 10x Genomics spatial ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...

Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to ...

If you are trying to work out whether 10x Genomics is attractively priced or already reflecting a lot of optimism, the starting point is understanding how its current market value lines up with the ...

Investors usually find it discouraging when an analyst cuts the price target on one of their stocks. In this instance, the cut to this company's shares was rather deep. It wasn't immediately apparent ...

PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS) ...

Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader ...

SPT Labtech and 10x Genomics have partnered to provide automated workflows for single cell research. The collaboration will allow scientists to scale experiments on 10x’s Chromium Single Cell platform ...